News

EMA updates regulatory science priorities

EMA updates regulatory science priorities

Gaps exist in regulatory science that need to be addressed to improve medicine development and evaluation, ultimately to enable access to innovative medicines that address patients’ needs. The European Medicines Agency (EMA) has outlined approximately one hundred...

read more...
EMA launches public consultation on RWD quality framework

EMA launches public consultation on RWD quality framework

The European Medicines Agency (EMA) has launched a public consultation on the draft chapter dedicated to real-world data (RWD) within the Data Quality Framework for EU medicines regulation. This is essential for advancing the use of real-world evidence in regulatory...

read more...
Nobel Prize for microRNAs discovery in gene regulation

Nobel Prize for microRNAs discovery in gene regulation

This year's Nobel Prize in Medicine has been awarded to two American researchers: Dr. Victor Ambros and Dr. Gary Ruvkun, who discovered microRNAs (miRNAs), a new class of small RNA molecules that play a crucial role in gene regulation. Ambros and Ruvkun's discovery...

read more...
EU HTA regulation: boosting collaboration and guidance

EU HTA regulation: boosting collaboration and guidance

The European Commission has published a draft Regulation on Health Technology Assessment (HTA), focusing on joint scientific consultations for medicinal products for human use and how developers can receive early guidance on the evidence and data needed to carry out a...

read more...
ICH M14: pharmacoepidemiological studies with RWD

ICH M14: pharmacoepidemiological studies with RWD

In May 2024, the International Council for Harmonisation (ICH) released the M14 guideline “ICH M14 Guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines. This...

read more...